Who are Group D : Dexmedetomidine + propofol group's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/group-d-dexmedetomidine-propofol-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Group D : Dexmedetomidine + propofol group — Competitive Intelligence Brief

Group D : Dexmedetomidine + propofol group (Group D : Dexmedetomidine + propofol group) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist). Area: Anesthesiology / Critical Care.

marketed Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist) Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol) Anesthesiology / Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Group D : Dexmedetomidine + propofol group (Group D : Dexmedetomidine + propofol group) — Seoul National University Hospital. Dexmedetomidine and propofol are combined to provide sedation and anesthesia through alpha-2 adrenergic receptor agonism and GABA-A receptor potentiation, respectively.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Group D : Dexmedetomidine + propofol group TARGET	Group D : Dexmedetomidine + propofol group	Seoul National University Hospital	marketed	Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist)	Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist) class)

Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Group D : Dexmedetomidine + propofol group — Competitive Intelligence Brief. https://druglandscape.com/ci/group-d-dexmedetomidine-propofol-group. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab